Journal article
PF625 VENETOCLAX FOR THE TREATMENT OF TRANSLOCATION (11; 14) AL AMYLOIDOSIS
Abstract
Venetoclax is a B cell lymphoma 2 (BCL‐2) inhibitor that has shown activity as a single agent and in combination with other therapies in patients with multiple myeloma, particularly those harboring t(11;14) associated with high BCL‐2 expression. Approximately 50% of patients with immunoglobulin light chain (AL) amyloidosis have t (11;14), making venetoclax a suitable agent to consider in treating patients with this rare disease. Data with …
Authors
Sidiqi MH; Al Saleh AS; Leung N; Aljama M; Jevremovic D; Gonsalves W; Buadi F; Kourelis T; Warsame R; Muchtar E
Journal
HemaSphere, Vol. 3, No. S1, pp. 265–266
Publisher
Wiley
Publication Date
6 2019
DOI
10.1097/01.hs9.0000560784.48139.c9
ISSN
2572-9241